LYEL Insider Trading Activity and SEC Form 4 Filings
LYEL insider trading summary
Over the past 12 months, insiders at Lyell Immunopharma, Inc. (LYEL) reported 28 open-market purchases worth $525.0M by 14 insiders and 28 sales worth $602K by 7 insiders on SEC Form 4. Net insider buying was $524.4M.
Latest LYEL insider buys and sells
| Date | Insider | Role | Type | Value |
|---|---|---|---|---|
| Nov 4, 2026 | Clinton Bybee | 10% Owner | Buy | $25.0M (2,321,262 @ $10.77) |
| Nov 4, 2026 | Robert Nelsen | 10% Owner | Buy | $25.0M (2,321,262 @ $10.77) |
| Nov 4, 2026 | Kristina Burow | 10% Owner | Buy | $25.0M (2,321,262 @ $10.77) |
| Nov 4, 2026 | Paul L Berns | 10% Owner | Buy | $25.0M (2,321,262 @ $10.77) |
| Nov 4, 2026 | ARCH Venture Partners XIII, L.P. | 10% Owner | Buy | $25.0M (2,321,262 @ $10.77) |
| Nov 4, 2026 | Steven Gillis | 10% Owner | Buy | $25.0M (2,321,262 @ $10.77) |
| Nov 4, 2026 | ARCH Venture Fund XIII, L.P. | 10% Owner | Buy | $25.0M (2,321,262 @ $10.77) |
| Nov 4, 2026 | Keith Crandell | 10% Owner | Buy | $25.0M (2,321,262 @ $10.77) |
| Nov 4, 2026 | ARCH Venture Partners XIII, LLC | 10% Owner | Buy | $25.0M (2,321,262 @ $10.77) |
| Nov 4, 2026 | ARCH Venture Partners IX, LLC | 10% Owner | Buy | $25.0M (2,321,262 @ $10.77) |
Source: SEC Form 4 filings. Open-market purchases (code P) and sales (code S) only; option exercises, grants and gifts are excluded.